drugset
drugset / Trial / NCT06282874

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

NCT06282874 ↗

Phase 4 Active not recruiting 41 enrolled Guangdong Association of Clinical Trials
NaSingle-groupOpen-labelTreatment

Summary

This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases.

Timeline

Start
2024-08-01
Primary completion
2026-04-30
Completion
2027-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorlatinib Small molecule 100 mg —

Indications

metastatic malignant neoplasm in the brain neoplastic meningitis non-small cell lung carcinoma